Design, synthesis, anticancer evaluation and docking studies of new pyrimidine derivatives as potent thymidylate synthase inhibitors
作者:Lamia H.T. Amin、Taghreed Z. Shawer、Abeer M. El-Naggar、Hend M.A. El-Sehrawi
DOI:10.1016/j.bioorg.2019.103159
日期:2019.10
anticancer activity were further assessed for their ability to inhibit thymidylate synthase (TS) enzyme. All the tested compounds demonstrated a marked TS inhibitory activity (33.66–74.98%), with IC50 ranging from 3.89 to 15.74 nM. Moreover, apoptosis studies were conducted on the most potent compound 8, to evaluate its proapoptotic potential. Interestingly, compound 8 induced the level of active caspase
对于研究人员来说,癌症是一个困惑而具有挑战性的问题。在这项研究中,设计,合成和评估了一系列6-芳基-5-氰基-嘧啶衍生物对HePG-2,MCF-7和HCT-116细胞系的抗癌活性。化合物2,3D,4A-C ,5,8和12显示高的抗癌活性,比得上5-氟尿嘧啶。此外,进一步评估了那些具有有效抗癌活性的化合物抑制胸苷酸合酶(TS)酶的能力。所有测试的化合物均表现出显着的TS抑制活性(33.66–74.98%),IC 50为3.89至15.74 nM。此外,针对最有效的化合物8进行了细胞凋亡研究,以评估其凋亡潜力。有趣的是,与对照相比,化合物8诱导了活性胱天蛋白酶3的水平,并且使Bax / Bcl2比提高了44倍。最后,进行了分子对接研究,以检测活性化合物与胸苷酸合酶活性位点之间可能的相互作用。